Axim Biotechnologies (AXIM) 0.3200 $AXIM
Medical Marijuana, Inc.'s Investment, AXIM Biotech, Launches World's First Cannabigerol (CBG) Clinical Trials on Psoriasis and Eczema
Marketwired - Tue May 17, 1:06PM CDT
MJNA's Cannabis-Based Drug Development R&D Plans Expand With AXIM Biotech's Clinical Trials on Patent-Pending AX-1602 Including Cannabigerol (CBG)
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
GlobeNewswire - Tue May 17, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema. Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.
Medical Marijuana, Inc.'s "420" News: Hemp Brands and Investments Capture Attention of Fox Business, CNN Money, Yahoo Beauty and More
Marketwired - Thu Apr 21, 8:02AM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded U.S. cannabis stock, is pleased to announce to the Company's shareholders and the public that many of its portfolio brands and investments were featured in "420" mainstream news coverage.
Medical Marijuana, Inc. Announces Its Cannabis Drug Research and Drug Development Pipeline Update
Marketwired - Wed Apr 20, 2:04PM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA) is pleased to announce that the "Company of Firsts" investments are actively fostering cannabis-based drug development and creation of new, innovative medicine delivery methods. These results are intended to expedite the historic reintroduction of cannabis-based medications into U.S. and global healthcare systems.
AXIM Biotech CEO Appointed to American Pain Association Board of Advisors, Addresses American Opioid Abuse Epidemic
GlobeNewswire - Thu Mar 31, 8:00AM CDT
Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotechnologies, Inc. (OTC:AXIM) was recently appointed to the American Pain Association (APA)'s Board of Advisors. AXIM Biotech holds more than 15 years of cannabis-based research and development knowledge of non-addictive pain alleviating alternatives to highly addictive opioid-based medications. The APA Board is appealing to the Surgeon General of the United States to actively address the nation's largest epidemic: prescription opioid pain medication abuse.
AXIM Biotechnologies Expands Executive Team and Advisory Board With Finance and Pro Sports Leaders: Seth Yakatan and Marvin Washington
GlobeNewswire - Thu Jan 28, 7:59AM CST
AXIM Biotechnologies (OTC:AXIM) is proud to announce the following finance and community outreach-focused additions to the Company's advisory board:
UPDATE - AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Thu Jan 28, 7:55AM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).
AXIM Biotechnologies Featured in Marijuana Documentary "Cannabis is Medicine"
GlobeNewswire - Wed Jan 13, 8:15AM CST
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce that the Company's efforts on clinical development of a patented cannabinoid-based medical chewing gum will be featured in a documentary to be released in the first quarter of 2016. The documentary Cannabis is Medicine is produced by Jordan Guzzardo, Emmy award-winning documentarian and photojournalist.
Medical Marijuana, Inc. Investment - AXIM Biotech - Featured by Reuters; Cannabis "Gum to Treat Multiple Sclerosis" Pain and Spasticity
GlobeNewswire - Wed Jan 06, 8:00AM CST
Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM Biotechnologies, Inc. (OTC:AXIM), was recently featured in a Health article by Reuters global news agency. The article profiles AXIM's role in developing the world's first patented cannabinoid release chewing gum (i.e. THC, CBD, CBG, etc.) - MedChew Rx(TM) - for pain and spasticity in multiple sclerosis (MS).
AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Tue Jan 05, 12:39PM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).
AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity With MS, Plans to Enter General Pain Market
GlobeNewswire - Thu Aug 20, 8:37AM CDT
News of clinical trials on a new pharmaceutical cannabis chewing gum treatment option for pain and spasticity in Multiple Sclerosis (MS) patients by AXIM Biotechnologies, Inc. (OTC:AXIM) is spreading. Initial reports include: Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money, Marijuana Stocks Report, Culture Magazine, and Pharmacy Choice.
MJNA's Investment Company AXIM Biotech Announces Clinical Trial Launch of MedChew RX for Treatment of Pain and Spasticity in Multiple Sclerosis and Development of Pharmaceutical Cannabis Chewing Gum
GlobeNewswire - Thu Aug 13, 8:00AM CDT
Medical Marijuana, Inc. (OTC Pink:MJNA) is an agricultural hemp industry innovator that sources, evaluates, invests in and acquires value-adding companies with a focus on industrial hemp. The Company is pleased to announce that one of its investments - AXIM Biotechnologies, Inc. (OTC:AXIM) - is conducting clinical trials of its patented pharmaceutical chewing gum MedChew(TM) RX in Europe. The cannabinoid controlled-release chewing gum is the first of its kind and is being developed for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).
AXIM Biotech Announces Launch of Clinical Trials on MedChew RX(TM) and Development of Pharmaceutical-Grade Cannabis Chewing Gum
GlobeNewswire - Tue Aug 11, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products - all derived from industrial hemp. AXIM Biotech is pleased to announce that the Company has started clinical development of its leading patented pharmaceutical chewing gum, MedChew RX(TM), for registration as a drug for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).
AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC
GlobeNewswire - Fri Jul 31, 7:00PM CDT
A statement from AXIM Biotechnologies (OTC:AXIM), an innovative biotechnology company:
Medical Marijuana, Inc.'s CanChew -- Patented Cannabis Gum -- Featured in ABC, NBC, CBS, Yahoo! News and More From Chicago Cannabis Convention
GlobeNewswire - Thu Jul 30, 8:00AM CDT
As Illinois implements the state's accessibility to medical cannabis, many patients, healthcare and legal professionals exchanged knowledge and resources at the 2 annual My Compassion Chicago Cannabis Conference at Navy Pier July 23-25. There, CanChew, the first patented cannabis chewing gum, was sampled by show goers. CanChew also captured the attention of both mainstream and industry news reporters in features including: ABC, NBC, CBS, Yahoo News, Telemundo, WGN, Marijuana Investor News and more.
AXIM Biotech Presents Patented Cannabinoid Delivery Methods at My Compassion's Chicago Cannabis Conference
GlobeNewswire - Wed Jul 29, 7:59AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) CEO George E. Anastassov, MD, DDS, MBA, proudly shared the Company's cannabinoid delivery methods - including the world's first patented cannabinoid release chewing gum - at the My Compassion Chicago Cannabis Conference. The three-day conference took place at Chicago's Navy Pier and focused on medical cannabis and hemp education with patients, industry professionals and the public.
Medical Marijuana, Inc.'s Video Statement on Investment Portfolio's Historic Accomplishments and Supporting the Science Behind Cannabis Legalization
GlobeNewswire - Wed Jul 15, 9:15AM CDT
"Honestly, if you and I would have sat here two or three years ago, people would be saying, 'I would never invest in marijuana stocks,'" states Andrew Hard, CEO of CMW Media and Spokesperson for Medical Marijuana, Inc. (Pink Sheets:MJNA) during an interview by Cannabis Financial Network (CFN). "Literally, we are here at the show today with the International Cannabis Association in the middle of New York City - where I used to work as a journalist for over a decade. People here are asking, 'HOW can I invest my money into this industry?' and 'WHERE should I put it?' So we are light years away from where we were just a couple years before."
Medical Marijuana, Inc.'s Investment, AXIM Biotech, Launches World's First Cannabigerol (CBG) Clinical Trials on Psoriasis and Eczema
Marketwired - Tue May 17, 1:06PM CDT
MJNA's Cannabis-Based Drug Development R&D Plans Expand With AXIM Biotech's Clinical Trials on Patent-Pending AX-1602 Including Cannabigerol (CBG)
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
GlobeNewswire - Tue May 17, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema. Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.
Medical Marijuana, Inc.'s "420" News: Hemp Brands and Investments Capture Attention of Fox Business, CNN Money, Yahoo Beauty and More
Marketwired - Thu Apr 21, 8:02AM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded U.S. cannabis stock, is pleased to announce to the Company's shareholders and the public that many of its portfolio brands and investments were featured in "420" mainstream news coverage.
Medical Marijuana, Inc. Announces Its Cannabis Drug Research and Drug Development Pipeline Update
Marketwired - Wed Apr 20, 2:04PM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA) is pleased to announce that the "Company of Firsts" investments are actively fostering cannabis-based drug development and creation of new, innovative medicine delivery methods. These results are intended to expedite the historic reintroduction of cannabis-based medications into U.S. and global healthcare systems.
AXIM Biotech CEO Appointed to American Pain Association Board of Advisors, Addresses American Opioid Abuse Epidemic
GlobeNewswire - Thu Mar 31, 8:00AM CDT
Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotechnologies, Inc. (OTC:AXIM) was recently appointed to the American Pain Association (APA)'s Board of Advisors. AXIM Biotech holds more than 15 years of cannabis-based research and development knowledge of non-addictive pain alleviating alternatives to highly addictive opioid-based medications. The APA Board is appealing to the Surgeon General of the United States to actively address the nation's largest epidemic: prescription opioid pain medication abuse.
AXIM Biotechnologies Expands Executive Team and Advisory Board With Finance and Pro Sports Leaders: Seth Yakatan and Marvin Washington
GlobeNewswire - Thu Jan 28, 7:59AM CST
AXIM Biotechnologies (OTC:AXIM) is proud to announce the following finance and community outreach-focused additions to the Company's advisory board:
UPDATE - AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Thu Jan 28, 7:55AM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).
AXIM Biotechnologies Featured in Marijuana Documentary "Cannabis is Medicine"
GlobeNewswire - Wed Jan 13, 8:15AM CST
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce that the Company's efforts on clinical development of a patented cannabinoid-based medical chewing gum will be featured in a documentary to be released in the first quarter of 2016. The documentary Cannabis is Medicine is produced by Jordan Guzzardo, Emmy award-winning documentarian and photojournalist.
Medical Marijuana, Inc. Investment - AXIM Biotech - Featured by Reuters; Cannabis "Gum to Treat Multiple Sclerosis" Pain and Spasticity
GlobeNewswire - Wed Jan 06, 8:00AM CST
Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM Biotechnologies, Inc. (OTC:AXIM), was recently featured in a Health article by Reuters global news agency. The article profiles AXIM's role in developing the world's first patented cannabinoid release chewing gum (i.e. THC, CBD, CBG, etc.) - MedChew Rx(TM) - for pain and spasticity in multiple sclerosis (MS).
AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Tue Jan 05, 12:39PM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).
AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity With MS, Plans to Enter General Pain Market
GlobeNewswire - Thu Aug 20, 8:37AM CDT
News of clinical trials on a new pharmaceutical cannabis chewing gum treatment option for pain and spasticity in Multiple Sclerosis (MS) patients by AXIM Biotechnologies, Inc. (OTC:AXIM) is spreading. Initial reports include: Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money, Marijuana Stocks Report, Culture Magazine, and Pharmacy Choice.
MJNA's Investment Company AXIM Biotech Announces Clinical Trial Launch of MedChew RX for Treatment of Pain and Spasticity in Multiple Sclerosis and Development of Pharmaceutical Cannabis Chewing Gum
GlobeNewswire - Thu Aug 13, 8:00AM CDT
Medical Marijuana, Inc. (OTC Pink:MJNA) is an agricultural hemp industry innovator that sources, evaluates, invests in and acquires value-adding companies with a focus on industrial hemp. The Company is pleased to announce that one of its investments - AXIM Biotechnologies, Inc. (OTC:AXIM) - is conducting clinical trials of its patented pharmaceutical chewing gum MedChew(TM) RX in Europe. The cannabinoid controlled-release chewing gum is the first of its kind and is being developed for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).
AXIM Biotech Announces Launch of Clinical Trials on MedChew RX(TM) and Development of Pharmaceutical-Grade Cannabis Chewing Gum
GlobeNewswire - Tue Aug 11, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products - all derived from industrial hemp. AXIM Biotech is pleased to announce that the Company has started clinical development of its leading patented pharmaceutical chewing gum, MedChew RX(TM), for registration as a drug for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).
AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC
GlobeNewswire - Fri Jul 31, 7:00PM CDT
A statement from AXIM Biotechnologies (OTC:AXIM), an innovative biotechnology company:
Medical Marijuana, Inc.'s CanChew -- Patented Cannabis Gum -- Featured in ABC, NBC, CBS, Yahoo! News and More From Chicago Cannabis Convention
GlobeNewswire - Thu Jul 30, 8:00AM CDT
As Illinois implements the state's accessibility to medical cannabis, many patients, healthcare and legal professionals exchanged knowledge and resources at the 2 annual My Compassion Chicago Cannabis Conference at Navy Pier July 23-25. There, CanChew, the first patented cannabis chewing gum, was sampled by show goers. CanChew also captured the attention of both mainstream and industry news reporters in features including: ABC, NBC, CBS, Yahoo News, Telemundo, WGN, Marijuana Investor News and more.
AXIM Biotech Presents Patented Cannabinoid Delivery Methods at My Compassion's Chicago Cannabis Conference
GlobeNewswire - Wed Jul 29, 7:59AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) CEO George E. Anastassov, MD, DDS, MBA, proudly shared the Company's cannabinoid delivery methods - including the world's first patented cannabinoid release chewing gum - at the My Compassion Chicago Cannabis Conference. The three-day conference took place at Chicago's Navy Pier and focused on medical cannabis and hemp education with patients, industry professionals and the public.
Medical Marijuana, Inc.'s Video Statement on Investment Portfolio's Historic Accomplishments and Supporting the Science Behind Cannabis Legalization
GlobeNewswire - Wed Jul 15, 9:15AM CDT
"Honestly, if you and I would have sat here two or three years ago, people would be saying, 'I would never invest in marijuana stocks,'" states Andrew Hard, CEO of CMW Media and Spokesperson for Medical Marijuana, Inc. (Pink Sheets:MJNA) during an interview by Cannabis Financial Network (CFN). "Literally, we are here at the show today with the International Cannabis Association in the middle of New York City - where I used to work as a journalist for over a decade. People here are asking, 'HOW can I invest my money into this industry?' and 'WHERE should I put it?' So we are light years away from where we were just a couple years before."
